$RXMD - "Due to the company’s performance and growth trajectory, terms were negotiated to be significantly more favorable than were previously available. The Company has secured this capital in advance of an ambitious 2019 agenda which includes logistical implementation of the company’s unique service offerings (DischargeRx, TelePharmacy, Full Service 340B Program), development of new product lines and digital technologies, expanded sales efforts of the core business, build-out of the recently acquired property, and acquisition support."
